dolutegravir: Clinical Trials

53 trials of dolutegravir, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

37 completed, 6 recruiting, 3 active not recruiting, 3 terminated. 53 Phase 3, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 353Completed 37, Recruiting 6, Active not recruiting 3, Terminated 3, Unknown 2, Not yet recruiting 1, Withdrawn 1
Phase 25Completed 3, Active not recruiting 1, Withdrawn 1

Follow dolutegravir: new trials by email Literature Review of dolutegravir trials Research Report on dolutegravir

Trials (filtered) newest first · largest first

All 53 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in Africa
Dolutegravir (DTG), Abacavir (ABC), Lamivudine (3TC) - HIV Infection
Phase 3Not yet recruitingUniversity College, London8002026-11-012026-08-28
A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV Treatment
Fostemsavir, Dolutegravir (DTG)/ Lamivudine (3TC) - HIV Infections
Phase 3RecruitingViiV Healthcare1972026-07-212026-11-13
Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment
Dolutegravir 50mg Tab, Dolutegravir/Lamivudine 50 MG-300mg Oral Tablet [DOVATO], Dolutegravir plus Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC) - Tuberculosis, HIV
Phase 3RecruitingJohns Hopkins University1502025-09-182026-09-11
Ndovu RCT: Investing the Optimal Management of Dolutegravir Resistance
Dolutegravir Pill, Darunavir+Ritonavir - HIV-1-infection
Phase 3RecruitingUniversity of Nairobi3922025-09-012025-09-11
DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection
Doravirine + tenofovir DF + lamivudine, Dolutegravir + tenofovir DF + lamivudine or emtricitabine - HIV-1-infection
Phase 3RecruitingANRS, Emerging Infectious Diseases6102025-01-272026-07-27
RolloverTreatment With Triumeq for People With ALS Following the Lighthouse II Trial
Abacavir 600mg, Lamivudine 300mg and Dolutegravir 50mg (Triumeq) - Amyotrophic Lateral Sclerosis, ALS
Phase 3TerminatedMacquarie University, Australia122024-11-152025-06-08
Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCT
APRETUDE (cabotegravir) 600 mg\3 mL, DAPIRING (Dapivirine) 25mg Vaginal Ring, tenofovir disoproxil and emtricitabine - HIV Infections
Phase 3RecruitingAfrica Health Research Institute20522024-02-272026-07-09
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
Dolutegravir, Lamivudine, Bictegravir - HIV, HIV Infections
Phase 3Active not recruitingViiV Healthcare4632024-02-212026-10-14
Improving HIV-1 Control in Africa With Long Acting Antiretrovirals
Cabotegravir/Rilpivirine, Antiretroviral - HIV-1-infection
Phase 3CompletedMRC/UVRI and LSHTM Uganda Research Unit5402022-12-082026-10-09
Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch
Doravirine, Dolutegravir, Triple cART regimen - HIV-1-infection
Phase 3RecruitingChelsea and Westminster NHS Foundation Trust1502022-08-172023-10-25
DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old
Dolutegravir (DTG) and lamivudine (3TC), SOC - HIV Infections
Phase 2 / Phase 3Active not recruitingPENTA Foundation3862022-04-222026-03-04
DTG Plus 3TC for Prophylaxis of Mother-to-child Transmission of HIV Infection in Pregnant Women
Dolutegravir plus lamivudine in a FDC - HIV Infections, Pregnancy Related
Phase 3CompletedFundação Bahiana de Infectologia202021-07-012023-10-04
Early DOlutegravir/LAmivudine Switching After Virological Suppression (EDOLAS Study)
DOVATO - HIV-1-infection
Phase 3UnknownSocieta' Italiana Di Malattie Infettive E Tropicali4402021-03-232021-07-28
ANRS 12372 MODERATO Study
dolutegravir, atazanavir boosted with ritonavir, tenofovir + lamivudine +efavirenz or dolutegravir + lamivudine + tenofovir - HIV-1-infection
Phase 3CompletedANRS, Emerging Infectious Diseases4802020-11-172026-10-16
Nucleosides And Darunavir/Dolutegravir In Africa
Darunavir, Ritonavir, Dolutegravir - Human Immunodeficiency Virus
Phase 3UnknownMakerere University4652019-07-302020-07-30
Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults
Dolutegravir + Lamivudine FDC - HIV Infections
Phase 3CompletedViiV Healthcare1312019-07-022021-10-21
Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents
DTG + 3TC FDC - HIV Infections
Phase 3CompletedViiV Healthcare322019-05-062025-12-09
Open-Label Multi-Centre Randomised Switch Study to Evaluate Virological Efficacy Over 96Weeks Of 2-Drug Therapy With Dolutegravir(DTG)/Rilpivirine(RPV) Fixed Dose Combination(FDC) in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTI Mutation K103N
Dolutegravir & Rilpivirine 2 drug fixed dose combined therapy - HIV-1-infection
Phase 3CompletedNEAT ID Foundation1402018-11-052024-12-24
Dolutegravir in Pregnant HIV Mothers and Their Neonates
Dolutegravir, Standard of Care (EFV + 2 NRTI backbone) - HIV-1-infection, Pregnancy Related
Phase 3CompletedUniversity of Liverpool2682018-01-222025-02-21
Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants
Dolutegravir, Emtricitabine/tenofovir alafenamide, Emtricitabine/tenofovir disoproxil fumarate - HIV Infections
Phase 3CompletedNational Institute of Allergy and Infectious Diseases (NIAID)6432018-01-192026-07-31

Showing 20 of 53. Sign in to see all of them.

Conditions studied

HIV Infections (25)  ·  Acquired Immunodeficiency Syndrome (15)  ·  Infections (11)  ·  Amyotrophic Lateral Sclerosis (1)  ·  Arthralgia (1)  ·  Breast Feeding (1)  ·  Coinfection (1)  ·  Osteoporosis (1)  ·  Tuberculosis (1)

Sponsors

ViiV Healthcare (20)  ·  ANRS, Emerging Infectious Diseases (4)  ·  Fundação Bahiana de Infectologia (2)  ·  Gilead Sciences (2)  ·  PENTA Foundation (2)  ·  University of Liverpool (2)  ·  Africa Health Research Institute (1)  ·  Babafemi Taiwo (1)  ·  Centre Hospitalier Régional d'Orléans (1)  ·  Chelsea and Westminster NHS Foundation Trust (1)  ·  Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia (1)  ·  IRCCS San Raffaele (1)  ·  Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba (1)  ·  Johns Hopkins University (1)  ·  MRC/UVRI and LSHTM Uganda Research Unit (1)

Countries

United States (21)  ·  France (20)  ·  Spain (19)  ·  Italy (16)  ·  United Kingdom (16)  ·  Germany (15)  ·  South Africa (15)  ·  Canada (13)  ·  Russia (11)  ·  Australia (10)  ·  Belgium (10)  ·  Argentina (8)  ·  Uganda (8)  ·  Brazil (7)  ·  Thailand (7)

Top investigators

Adriano Lazzarin, Prof (1)  ·  Alessandra Bandera, P.I. (1)  ·  Alessandro Bartoloni, P.I. (1)  ·  Andrea Andreoni, P.I. (1)  ·  Annamaria Cattelan, P.I. (1)  ·  Antonella Castagna, P.I. (1)  ·  Antonio Cascio, P.I. (1)  ·  Antonio Di Biagio, P.I. (1)  ·  Babafemi Taiwo, MBBS (1)

Results publications

PMID 29239893, PMID 31307948, PMID 31350995, PMID 34913844, PMID 40134635, PMID 24074642, PMID 24195548, PMID 24446523, PMID 24698485, PMID 24944232, PMID 25321146, PMID 26262777, PMID 26424673, PMID 28729158, PMID 28867499, PMID 29293895, PMID 29956087, PMID 30601976, PMID 30803969, PMID 30932951, PMID 31068270, PMID 31068272, PMID 31339676, PMID 31339677, PMID 31539371, PMID 32386721, PMID 32504574, PMID 32668455, PMID 32701823, PMID 32763217, PMID 33010240, PMID 33010241, PMID 33136751, PMID 33262331, PMID 33346335, PMID 33355914, PMID 33446115, PMID 33587500, PMID 33625064, PMID 33794181, PMID 33812487, PMID 33880558, PMID 34289276, PMID 34656207, PMID 34817414, PMID 34965338, PMID 34978890, PMID 35079789, PMID 35460601, PMID 35508986

NIH funding

2014 (3), 2015 (3), 2016 (3), 2017 (2), 2009 (1), 2019 (1), 2023 (1)